🇨🇭 Switzerland Country × Condition
astrocytoma grade iii Clinical Trials in Switzerland
Active clinical trials for astrocytoma grade iii with research sites in Switzerland. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇨🇭 Switzerland
Active Trials in Switzerland (2)
NCT05765812 Phase 1, Phase 2
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Enrollment
116 pts
Country
🇨🇭 Switzerland
Debiopharm International SA
View Trial → NCT06118723
Recruiting
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Enrollment
784 pts
Country
🇨🇭 Switzerland
Jasper Gerritsen
View Trial → Frequently Asked Questions
How many astrocytoma grade iii clinical trials are active in Switzerland?
There are currently 2 active clinical trials for astrocytoma grade iii with sites in Switzerland, of which 2 are actively recruiting patients.
How can I join a astrocytoma grade iii clinical trial in Switzerland?
To join a astrocytoma grade iii clinical trial in Switzerland, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Switzerland directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are astrocytoma grade iii trials in Switzerland?
Active astrocytoma grade iii trials in Switzerland span Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology